Pfizer hypes Advil line extension with TV ad, personal shopper offer

Share this article:
Pfizer hypes Advil line extension with TV ad, personal shopper offer
Pfizer hypes Advil line extension with TV ad, personal shopper offer
Pfizer Consumer Healthcare is launching an Advil line extension with a contest to win a personal shopper for “Black Friday,” the Friday after Thanksgiving, when bargain-hunting holiday shoppers pack stores.

Pfizer is hawking Advil Congestion Relief, a new Advil-plus-decongestant formula that promises to alleviate sinus pressure by easing nasal inflammation. The company is also airing TV ads by ghg titled “Don't blame mucus.” The message: snot's not the problem – inflammation is, as a man in a green shirt that reads “Mucus” attests. Advil, he says, is “The right sinus medicine for the real problem.”

Mr. Mucus, the star of Reckitt Benckiser's Mucinex campaign, will doubtless feel vindicated.

For the Black Friday campaign, shoppers at malls in the Jersey City, Atlanta, Chicago, Dallas and San Francisco areas can text for a chance to win a “personal Black Friday Decongester” who will help a hundred of them avoid congested stores. One grand prize winner in each market will also win a $1,000 gift card.

Pfizer flagged a recent poll that found around 70% of Americans avoid crowded or congested areas during the holidays.

Ketchum is handling PR for the Decongester campaign.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...